Comparing GlycoMimetics (NASDAQ:GLYC) & Fulcrum Therapeutics (NASDAQ:FULC)

GlycoMimetics (NASDAQ:GLYC) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares GlycoMimetics and Fulcrum Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics	$10,000.00	1,126.19	-$36.90 million	($0.58)	-0.30
Fulcrum Therapeutics	$81.63 million	6.87	-$97.33 million	($1.60)	-5.64

GlycoMimetics has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares GlycoMimetics and Fulcrum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlycoMimetics	N/A	-88.40%	-76.65%
Fulcrum Therapeutics	-3,470.05%	-8.28%	-7.61%

Risk & Volatility

GlycoMimetics has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GlycoMimetics and Fulcrum Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlycoMimetics	0	3	0	0	2.00
Fulcrum Therapeutics	0	0	7	0	3.00

GlycoMimetics currently has a consensus price target of $10.00, suggesting a potential upside of 5,624.10%. Fulcrum Therapeutics has a consensus price target of $15.57, suggesting a potential upside of 72.63%. Given GlycoMimetics’ higher probable upside, research analysts plainly believe GlycoMimetics is more favorable than Fulcrum Therapeutics.

About GlycoMimetics

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.